GILEAD	Post Market Query Template	GT-21043B (2.0)

Date: 15 June 2018 **MCN:** 2018-0339341

Dear Reporter

To comply with our global regulatory reporting obligations and as part of our pharmacovigilance process, we are required to report adverse events that may be associated with our product. Patient confidentiality will be maintained in accordance with applicable laws/policies.*

We received the following report on **14 MAY 2018** for your patient who was treated with **Harvoni**.

Patient: **MM** DOB: **10-APR-1979** Age: **Not Reported** Gender: **Male**

Adverse Event(s): **Anemia**

Patient Information:

Initials: M.M. ***Date of Birth:*** 10 Apr 1979 (DD/MMM/YYYY) ***Age Group:*** ☐ Child (<18 yrs.) ☒ Adult (≥ 18 yrs. < 65 yrs.) ☐ Elderly (≥ 65 yrs.)

Sex: ☒ Male ☐ Female

Race: ☒ Caucasian ☐ Hispanic ☐ Of African Descent ☐ Asian ☐ Other (specify) _____

Age at onset of event: _____(yrs.) ***Height:*** 172 ☐ in ☒ cm ***Weight:*** 90 ☐ lb ☒ kg

Adverse Event(s): Adverse Event Description (provide diagnosis, if known) **Append separate sheet, if necessary**	***Causality*** Was the event considered related to Gilead drug? (Yes/No)	***Resulted in*** (Check any that apply) [1](A) Hospitalization (B) Disability (C) Life-threatening (D) Congenital Anomaly [2](E) Death	***Outcome*** (A) Resolved (B) Not Resolved (C) Unknown (D) Fatal (died due to event)	***Event Start Date*** (DD/MMM/YYYY)	***Event Stop Date*** (DD/MMM/YYYY)
1 Anemia	No	A☐ B☐ C☐ D☐ E☐	A☒ B☐ C☐ D☐	19 Apr 2018	14 Jun 2018
2.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
3.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
4.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
5.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
6.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
7.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		
8.		A☐ B☐ C☐ D☐ E☐	A☐ B☐ C☐ D☐		

[1] **If Adverse event resulted in hospitalization, please provide dates:** _____ (DD/MMM/YYYY) **to** _____ (DD/MMM/YYYY)

[2] **For Fatal events please provide autopsy report and date of death:** _____ (DD/MMM/YYYY)

MCN: 2018-0339341

Summary of Event(s) / Other Relevant Information:

Please provide a short summary of the event(s) and include any treatment given, **relevant medical history**, **risk factors**, and the results of any supportive laboratory data or other investigations (append results separately, if necessary). Before HCV treatment, the level of hemoglobin (Hgb) was 10. After first month of treatment on 19 April, 2018 Hgb decreased up to 7. Then Hgb level gradually increased - on 17 May Hgb level became 9; on 14 June - 9,5.

If medical intervention was required to prevent the reported event becoming serious, please check here ☐ and briefly describe the clinical course.

Medication Details - including Gilead drug(s):

*List **all** medications (including non-prescription and herbal preparations) the patient was receiving at the time of the event(s). **Append separate sheet, if necessary.***

	Name	Dose	Route	Start Date (DD/MMM/YYYY)	Stop Date (DD/MMM/YYYY)	Indication	Lot/Batch No.	Suspect Drug* Yes/No
1.	Marvoni	400/90mg	PO	22 Mar 2018	ongoing	chronic HCV		
2.								
3.								
4.								
5.								
6.								
7.								
8.								

** Yes = Considered to be causally associated with the reported event(s) No = Considered to NOT be causally associated with the reported event(s)*

Action taken with Gilead Drug(s):

Due to the event, was the dosage of the Gilead drug(s):

☒ Continued unchanged ☐ Discontinued ☐ Reduced (new dosage _____) ☐ Unknown

If the dose was reduced or drug discontinued, did the symptoms:

☐ Resolve ☐ Improve ☐ Remain the same

If the Gilead drug was restarted, did the event reappear? ☐ No ☐ Yes (please provide details)

If the requested information is not available, please provide a response to this query indicating that the requested information is not available.

Please respond via E-mail: Safety_FC@gilead.com or Fax: 1-650-522-5477

If you need to speak with someone, please call **650-522-5114** and leave a voice message **including the MCN number** noted on the form, the **Gilead product** involved, **your name**, and **your phone number**. Thank you for your assistance with this case.

Kind regards,
Your name

Please be aware that information provided to Gilead relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by Gilead in accordance with applicable data protection laws and the Gilead privacy policy, available to you either on www.gilead.com/privacy or upon request.

HISTORY OF REVISIONS

Effective Date	Version	Author	Description of Changes
Refer to EDMS	2.0	Peregrin Angeles	Administrative Change: Changed from ".dotx" to ".docx" file type.
07-Jun-2017	1.0	Grace Liu	New Template.